Anthrax Clinical Trial
Official title:
A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers
The purpose of this study is to assess the safety and immunogenicity of rPA102 vaccine given intramuscularly at 0 and 4 weeks over 2 dose ranges and 4 adjuvant levels.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00114621 -
Anthrax Vaccine Clinical Trials
|
Phase 1 | |
| Recruiting |
NCT00050310 -
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
|
||
| Completed |
NCT01453907 -
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01491607 -
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
|
Phase 3 | |
| Completed |
NCT03518125 -
BARDA Securing Anthrax Immunity For the Elderly
|
Phase 2 | |
| Completed |
NCT04660201 -
Anthrax AV7909 Liquid vs Lyophilized
|
Phase 1 | |
| Completed |
NCT04320485 -
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
|
||
| Recruiting |
NCT06365073 -
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
|
||
| Completed |
NCT03877926 -
VELOCITY: An Anthrax Vaccine Clinical Study
|
Phase 3 | |
| Completed |
NCT03498027 -
Febrile Whole Blood Specimen Collection and Testing
|
||
| Terminated |
NCT00964834 -
Ph1 Study of Valortim and Doxycycline in Humans
|
Phase 1 | |
| Completed |
NCT00063843 -
Anthrax-rPA: Safety, Tolerability, Immunogenicity
|
Phase 1 | |
| Completed |
NCT01624532 -
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
|
Phase 2 | |
| Completed |
NCT04148118 -
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT05672875 -
Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
|
||
| Completed |
NCT01770743 -
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
|
Phase 2 | |
| Completed |
NCT00845650 -
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
|
Phase 1/Phase 2 | |
| Completed |
NCT01867957 -
Efficacy and Safety of Anthrax Vaccine, GC1109
|
Phase 1 | |
| Completed |
NCT00031291 -
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
|
N/A | |
| Not yet recruiting |
NCT03569514 -
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
|